Business Description
Fate Therapeutics Inc
NAICS : 325412
SIC : 2836
ISIN : US31189P1021
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 3.04 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.28 | |||||
Debt-to-EBITDA | -0.6 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -1.66 | |||||
Beneish M-Score | -4.16 | |||||
WACC vs ROIC |
Growth Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 19.1 | |||||
3-Year EBITDA Growth Rate | -4.9 | |||||
3-Year EPS without NRI Growth Rate | -3.1 | |||||
3-Year FCF Growth Rate | -37.9 | |||||
3-Year Book Growth Rate | -5.2 | |||||
Future 3-5Y EPS without NRI Growth Rate | 27.7 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 1.57 | |||||
9-Day RSI | 8.47 | |||||
14-Day RSI | 17.72 | |||||
6-1 Month Momentum % | 281.47 | |||||
12-1 Month Momentum % | 17.1 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 8.48 | |||||
Quick Ratio | 8.48 | |||||
Cash Ratio | 8.06 | |||||
Days Sales Outstanding | 66.85 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4 | |||||
Shareholder Yield % | 1.34 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -299.86 | |||||
Net Margin % | -253.3 | |||||
FCF Margin % | -216.56 | |||||
ROE % | -37.07 | |||||
ROA % | -27.09 | |||||
ROIC % | -93.06 | |||||
ROC (Joel Greenblatt) % | -113.08 | |||||
ROCE % | -35.51 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 5.98 | |||||
PB Ratio | 1.04 | |||||
Price-to-Tangible-Book | 1 | |||||
EV-to-EBIT | -1.16 | |||||
EV-to-EBITDA | -1.28 | |||||
EV-to-Revenue | 3.47 | |||||
EV-to-Forward-Revenue | 57.18 | |||||
EV-to-FCF | -1.65 | |||||
Price-to-Net-Current-Asset-Value | 1.91 | |||||
Price-to-Net-Cash | 2.09 | |||||
Earnings Yield (Greenblatt) % | -86.57 | |||||
FCF Yield % | -32.09 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Fate Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 59.307 | ||
EPS (TTM) (€) | -1.519 | ||
Beta | 2.31 | ||
Volatility % | 97.69 | ||
14-Day RSI | 17.72 | ||
14-Day ATR (€) | 0.246166 | ||
20-Day SMA (€) | 5.23955 | ||
12-1 Month Momentum % | 17.1 | ||
52-Week Range (€) | 1.5455 - 7.758 | ||
Shares Outstanding (Mil) | 113.78 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Fate Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Fate Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Fate Therapeutics Inc Frequently Asked Questions
What is Fate Therapeutics Inc(STU:F6T)'s stock price today?
When is next earnings date of Fate Therapeutics Inc(STU:F6T)?
Does Fate Therapeutics Inc(STU:F6T) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |